Dr. Lal PathLabs Limited share price

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.Read more

Website NSE हिंदी में BSE

HealthcareDiagnostics & ResearchNifty 500 Nifty Smallcap 250NSE: LALPATHLABISIN INE600L01024

16 Oct 2026, 3:30 PM IST₹1,859.90▼ 25.20 (1.34%)

Market Cap₹ 31,100 Cr.
Current Price₹ 1,859.90
High / Low₹ 2,039 / 1,273
Stock P/E57.4
Book Value₹ 150
Dividend Yield1.06 %
ROCE25.7 %
ROE21.60 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 32.40
Price / Book12.38
OPM37.1 %
Debt / Equity0.08
Sales growth (5Y)11.8 %
Profit growth (5Y)11.4 %
Promoter holding54.7 %
EV / EBITDA37.9
Beta0.16
All-time high₹ 2,123

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
LALPATHLAB	-1.89%	+7.34%	+31.83%	+25.45%	+17.84%	+13.34%	+0.62%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Dr. Lal PathLabs Limited is in the Diagnostics & Research industry (Healthcare), with a market value of ₹31,100 crore.
It trades at 57.4 times its last 12 months' earnings and 12.4 times book value.
Revenue grew 11.8% a year over the last 5 years, profit 11.4% a year.
Return on equity was 21.6% and return on capital employed 25.7% in the latest year.
Debt was 0.08 times shareholders' equity.
The share price is 8.8% below its 52-week high and up 17.8% over one year.
Promoters and insiders hold about 54.7%; institutions about 32.4%.

Pros

Strong return on equity: 22.1% on average over the last 3 years.
Company is almost debt-free (debt is 0.08 times equity).
Latest quarter (Jun 2026): sales up 19% and profit up 27% from a year ago.
Pays a healthy dividend: about 44% of profit last year.
Institutional (FII + DII) holding has risen by 5.4 points over 3 years.

Cons

Trades at 12.4 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Dr. Lal PathLabs Limited

Employees: 5,206
Head office: Gurugram
NSE industry: Healthcare

HealthcareHealthcareDiagnostics & Research

Part ofNifty 500 Nifty Smallcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Dr. Lal PathLabs	1,859.90	57.4	31,100	1.06	171	27.24	798	19.10	25.7	21.6	12.38	37.1	0.08	54.70	2,763	11.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Apollo Hospitals Enterprise	7,890.00	54.3	1,13,446	0.25	581	49.05	7,044	25.95	19.2	21.9	11.97	11.7	0.90	28.39	24,911	14.8
6.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Max Healthcare Institute	846.00	56.7	82,342	0.23	323	4.87	2,366	16.70	12.6	14.3	7.66	22.8	0.32	28.20	8,225	22.4
10.	Abbott India	26,170.00	34.4	55,609	2.01	429	17.13	1,814	4.33	41.9	34.5	11.65	26.3	0.04	75.54	6,927	9.0
	Median: 12 Co.	1,809.35	49.2	1,04,879	0.75	573	11.00	5,939	18.79	18.5	19.7	11.81	24.2	0.15	53.35	19,332	12.6

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	541	601	539	545	602	660	597	603	670	731	660	703	798
YOY Sales Growth %	7.62%	12.65%	10.11%	11.08%	11.26%	9.80%	10.73%	10.49%	11.28%	10.66%	10.57%	16.61%	19.10%
	395	424	398	401	432	458	443	434	478	507	481	516	550
Material Cost %	21%	20%	20%	20%	20%	19%	20%	20%	19%	19%	20%	19%	19%
Employee Cost %	19%	18%	20%	19%	19%	19%	21%	19%	20%	18%	20%	18%	17%
Other Expenses %	33%	33%	34%	34%	33%	31%	33%	33%	32%	32%	33%	36%	33%
Operating Profit	146	178	141	145	170	203	154	169	192	224	179	187	248
OPM %	27%	30%	26%	27%	28%	31%	26%	28%	29%	31%	27%	27%	31%
	14	18	18	18	21	22	25	26	28	25	24	24	32
Exceptional items											-30
Interest	8	8	7	7	6	6	5	5	5	5	7	6	6
Depreciation	35	36	36	37	35	35	36	36	35	41	42	45	44
Profit before tax	118	152	116	120	150	183	138	153	181	204	124	160	229
	29%	27%	29%	28%	28%	29%	29%	-1%	26%	25%	26%	17%	25%
Current tax	38	43	34	33	45	48	40	39	45	47	40	27	60
Deferred tax	-4	-2	-1	2	-3	4	1	-41	2	4	-7	1	-2
	84	111	82	86	108	131	98	156	134	152	91	132	171
Minority share	1	1	1	1	1	2	1	1	2	2	1	1	1
Profit to shareholders	83	109	81	85	106	129	97	155	132	151	91	131	170
YOY Profit Growth %	43.64%	52.90%	53.36%	50.79%	28.95%	18.16%	19.34%	81.24%	24.30%	16.36%	-6.83%	-14.98%	27.24%
EPS in Rs	4.98	6.58	4.89	5.07	6.40	7.76	5.80	9.29	7.94	9.03	5.42	7.86	10.15
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	480	532	476	479	535	584	528	577	641	700	632	675	764
YOY Sales Growth %	9.29%	13.88%	11.11%	11.14%	11.33%	9.82%	10.95%	20.50%	19.87%	19.82%	19.69%	16.98%	19.31%
	344	369	346	349	379	399	383	418	457	485	458	494	526
Material Cost %	21%	20%	19%	20%	20%	19%	19%	19%	19%	19%	19%	19%	19%
Employee Cost %	19%	17%	20%	19%	19%	18%	21%	19%	20%	18%	20%	18%	16%
Other Expenses %	32%	33%	34%	34%	32%	31%	32%	34%	33%	32%	33%	36%	34%
Operating Profit	136	163	130	130	156	185	145	159	183	215	174	182	239
OPM %	28%	31%	27%	27%	29%	32%	28%	28%	29%	31%	27%	27%	31%
	15	14	15	16	29	22	30	25	26	23	27	37	30
Exceptional items											-30
Interest	7	7	7	6	6	5	5	5	5	5	7	6	6
Depreciation	18	19	19	20	18	18	19	35	33	39	40	43	40
Profit before tax	125	151	120	121	161	183	151	145	172	195	123	170	222
	25%	25%	26%	26%	24%	26%	24%	-2%	25%	25%	25%	17%	25%
Current tax	36	40	32	30	41	44	37	38	41	45	38	27	57
Deferred tax	-4	-2	-1	1	-2	4	0	-42	2	4	-7	2	-1
	94	113	88	90	123	135	115	148	129	146	92	141	166
YOY Profit Growth %	17.59%	43.77%	41.51%	25.35%	31.30%	19.65%	29.67%	65.81%	5.21%	7.77%	-19.56%	-4.92%	28.31%
EPS in Rs	5.64	6.80	5.39	5.37	7.38	8.12	6.87	8.90	7.76	8.73	5.52	8.45	9.94
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,057	1,057	1,203	1,330	1,581	2,087	2,017	2,227	2,461	2,763	2,891
YOY Sales Growth %			13.86%	10.55%	18.86%	32.01%	-3.38%	10.40%	10.55%	12.25%
	793	793	910	987	1,145	1,527	1,527	1,617	1,766	1,980	2,053
Material Cost %	21%	21%	22%	22%	25%	24%	22%	20%	20%	19%	19%
Employee Cost %	17%	17%	17%	18%	17%	17%	19%	19%	20%	18%	18%
Other Expenses %	37%	37%	36%	33%	30%	32%	35%	33%	33%	34%	33%
Operating Profit	264	264	294	344	436	561	490	609	696	783	838
OPM %	25%	25%	24%	26%	28%	27%	24%	27%	28%	28%	29%
	31	31	46	55	51	53	42	69	93	101	105
Exceptional items										-30	-30
Interest	1	1	1	15	16	30	38	29	22	23	24
Depreciation	33	33	38	73	77	108	150	144	142	162	172
Profit before tax	261	261	301	311	394	475	344	506	625	669	717
	34%	34%	33%	27%	25%	26%	30%	28%	21%	24%	24%
Current tax	93	93	104	84	102	127	108	148	172	159
Deferred tax	-3	-3	-4	-1	-4	-2	-5	-5	-40	0
	172	172	201	228	297	350	241	362	492	510	546
Minority share	1	1	1	2	5	6	2	5	5	5	4
Profit to shareholders	171	171	199	226	292	345	239	358	487	505	542
YOY Profit Growth %			16.71%	13.52%	30.27%	18.15%	-31.17%	50.27%	35.85%	3.58%
EPS in Rs	10.43	10.43	12.10	13.71	17.67	20.85	14.41	21.53	29.24	30.24	32.46
Dividend Payout %							43%	56%	43%	44%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 11%
TTM:: 14%

Compounded Profit Growth

5 Years:: 11%
3 Years:: 28%
TTM:: 5%

Stock Price CAGR

5 Years:: 1%
3 Years:: 13%
1 Year:: 18%

Return on Equity

4 Years:: 20%
Last Year:: 22%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,024	1,024	1,165	1,274	1,491	1,873	1,769	1,967	2,352	2,648	2,771
YOY Sales Growth %			13.76%	9.33%	17.03%	25.64%	-5.54%	11.18%	19.56%	12.59%
	768	768	882	946	1,083	1,363	1,308	1,408	1,686	1,894	1,963
Material Cost %	21%	21%	22%	23%	25%	24%	22%	20%	19%	19%	19%
Employee Cost %	17%	17%	17%	18%	17%	17%	18%	18%	19%	18%	18%
Other Expenses %	37%	37%	37%	34%	30%	32%	34%	33%	33%	34%	34%
Operating Profit	256	256	283	328	407	510	461	559	666	754	809
OPM %	25%	25%	24%	26%	27%	27%	26%	28%	28%	28%	29%
	32	32	47	58	51	53	47	60	112	113	116
Exceptional items										-30	-30
Interest	1	1	1	15	15	29	34	27	22	22	24
Depreciation	31	31	36	68	70	75	82	77	134	154	161
Profit before tax	255	255	292	303	374	459	391	516	621	660	710
	34%	34%	33%	26%	25%	25%	25%	26%	20%	23%	23%
Current tax	91	91	101	80	99	118	101	138	163	151
Deferred tax	-3	-3	-4	-1	-5	-3	-3	-6	-39	1
	168	168	195	223	280	344	292	384	497	508	545
YOY Profit Growth %			16.31%	14.23%	25.49%	22.85%	-15.02%	31.46%	29.37%	2.19%
EPS in Rs	10.26	10.26	11.87	13.55	16.97	20.81	17.64	23.13	29.85	30.45	32.64
Dividend Payout %							35%	52%	42%	44%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 14%
TTM:: 19%

Compounded Profit Growth

5 Years:: 13%
3 Years:: 20%
TTM:: 3%

Stock Price CAGR

5 Years:: 1%
3 Years:: 13%
1 Year:: 18%

Return on Equity

4 Years:: 20%
Last Year:: 22%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	83	83	84	168
Reserves	1,583	1,766	2,089	2,341
	419	247	157	199
Long term borrowings	83
Short term borrowings	153	83
	300	360	387	439
Trade payables	156	187	167	181
Minority interest	33	36	34	33
Current liabilities	470	464	402	451
Total Liabilities	2,386	2,456	2,717	3,146
	405	348	343	490
Gross block	780	796	865	1,102
Accumulated depreciation	375	448	522	613
Goodwill & intangibles	906	852	799	741
CWIP	4	5	7	6
	1,977	2,102	2,367	2,650
Inventories	34	37	36	44
Trade receivables	71	77	88	111
Cash & equivalents	264	361	293	243
Current assets	973	1,127	1,364	1,566
Total Assets	2,386	2,456	2,717	3,146

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	456	535	569	636
Profit for the year	239	358	487	505
Working capital changes	35	36	1	27
Direct taxes paid	-106	-132	-164	-175
	-287	-24	-303	-422
Fixed assets purchased	-45	-57	-54	-173
Fixed assets sold	1	1	1	1
Investments purchased	-1,135	-982	-1,572	-1,516
Investments sold	879	967	1,256	1,197
	-283	-414	-334	-264
Repayment of borrowings	-109	-153	-83
Interest paid	-38	-29	-22	-23
Dividends paid	-103	-201	-207	-223
Net Cash Flow	-114	97	-68	-50
Free Cash Flow	411	478	515	462

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	14.3%	20.4%	24.2%	21.6%
ROCE	—	19.9%	26.8%	28.0%	25.7%
Operating margin	—	17.1%	21.0%	36.5%	37.1%
Net margin	—	11.8%	16.1%	19.8%	18.3%
Debt / equity	—	0.25	0.13	0.07	0.08
Current ratio	—	2.07	2.43	3.39	3.48
Debtor days	—	13	13	13	15
Inventory days	—	17	18	27	30
Days payable	—	78	89	127	123
Cash conversion cycle	—	-48	-58	-87	-78
Working capital days	—	91	109	143	147

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 52.93%
FIIs 18.73%
DIIs 21.58%
Public 6.35%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	54.60%	54.60%	54.60%	53.92%	53.91%	53.91%	53.79%	53.21%	53.21%	53.21%	53.19%	52.93%
	25.35%	26.15%	25.42%	26.82%	26.82%	23.91%	21.68%	21.86%	20.29%	17.18%	17.36%	18.73%
Foreign portfolio investors (Cat. I)	24.12%	25.03%	23.86%	26.76%	26.71%	23.76%	21.56%	21.48%	19.94%	16.95%	16.71%	18.18%
Foreign portfolio investors (Cat. II)	1.24%	1.12%	1.57%	0.06%	0.11%	0.14%	0.13%	0.38%	0.35%	0.23%	0.64%	0.55%
	9.56%	9.69%	12.71%	12.89%	13.17%	16.08%	17.91%	18.49%	19.21%	21.38%	21.59%	21.58%
Mutual funds	5.88%	6.79%	9.30%	9.84%	10.25%	12.84%	15.04%	15.90%	16.84%	18.62%	18.79%	18.68%
Insurance companies	2.73%	2.30%	2.84%	2.54%	2.53%	2.75%	2.40%	2.09%	2.18%	2.33%	2.37%	2.46%
Banks								0.02%
Alternative investment funds	0.66%	0.31%	0.28%	0.22%	0.10%	0.20%	0.05%	0.07%	0.04%	0.28%	0.29%	0.28%
Government									0.01%	0.01%	0.01%
	10.12%	9.24%	6.96%	6.04%	5.82%	5.84%	6.23%	6.07%	6.94%	7.87%	7.47%	6.35%
Retail (up to ₹2 lakh)	7.11%	6.30%	4.78%	3.98%	3.89%	3.98%	4.15%	4.07%	4.56%	5.20%	4.97%	4.00%
HNIs (above ₹2 lakh)	0.15%	0.17%	0.13%	0.12%	0.12%	0.12%	1.08%	1.11%	1.26%	1.35%	1.28%	1.29%
NRIs	0.66%	0.61%	0.40%	0.35%	0.35%	0.36%	0.39%	0.42%	0.46%	0.56%	0.54%	0.43%
Bodies corporate	0.71%	0.47%	0.36%	0.30%	0.26%	0.24%	0.40%	0.26%	0.44%	0.52%	0.47%	0.40%
No. of Shareholders	1,49,901	1,46,741	1,31,189	1,16,606	1,16,236	1,15,699	1,18,656	1,12,703	1,16,167	1,14,527	1,11,037	1,13,559

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Dr. Lal PathLabs

No single fund or institution holds more than 1%.

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 18.68% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 23 Oct 2026
Ex-dividend date: 30 Jul 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Dr. Lal PathLabs Limited

What is the share price of Dr. Lal PathLabs Limited today?

Dr. Lal PathLabs Limited (LALPATHLAB) last traded at ₹1,859.90 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Dr. Lal PathLabs Limited?

About ₹31,100 crore at the latest price.

What is the P/E ratio of Dr. Lal PathLabs Limited?

About 57.4 times its earnings over the last 12 months.

Is Dr. Lal PathLabs Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Dr. Lal PathLabs Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Dr. Lal PathLabs Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Dr. Lal PathLabs Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Dr. Lal PathLabs

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Dr. Lal PathLabs Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next